Introduction
C-reactive protein (CRP) is an acute phase protein produced by the liver in acute inflammatory conditions. Elevated plasma level of CRP is predictive of cardiovascular diseases including myocardial infarction and stroke. [1] [2] [3] Plasma CRP is elevated in hypertension, 4 but it is not clear if this is a consequence of hypertension or if it contributes to the pathogenesis of hypertension, or both. There is some evidence, at least in women and elderly people, that CRP levels at baseline predicted the development of hypertension. 5, 6 However, the value of CRP in predicting hypertension is controversial. 7, 8 As hypertension is a common risk factor preceding cardiovascular events, it is worthwhile to investigate this relationship in a prospective study.
There have been few prospective studies investigating the causal relationship of plasma CRP and hypertension. 5, 6 Single-nucleotide polymorphisms (SNPs) in the gene encoding CRP (CRP) have been associated with plasma CRP level in several studies. [9] [10] [11] [12] [13] A genetic variant that was associated with the plasma level was used as an instrumental variable to assess the causal relationship between CRP and hypertension. 7 However, that study only genotyped a single SNP in a cross-sectional cohort of British elderly women. Moreover, there have been no prospective studies on the relationship between CRP and hypertension in Chinese. Such studies are especially indicated in view of ethnic differences in plasma CRP level, which has been reported to be lower in Asians. 14 For the same body mass index, Asians often have a greater degree of visceral adiposity and more cardiovascular risk factors, including hypertension, than Caucasians. 15 Besides plasma CRP level and adiposity, there are well-known ethnic differences in plasma renin level and responses to anti-hypertensive medication. 16 In this study, we investigated if a higher plasma CRP level is associated with hypertension development in a sample of the general population. We studied the common genetic variants in CRP and determined if they were related to plasma CRP level. We then tested if such genetic variants were associated with prevalent or incident hypertension in a population-based prospective cohort of Hong Kong Chinese.
Methods

Subjects
The Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS) is a cohort study of cardiovascular risk factors in Hong Kong Chinese. [17] [18] [19] In 1995-1996 (CRISPS-1), a random sample of 2895 Hong Kong Chinese subjects (1412 men and 1483 women, aged 25-74 years), representative of the general population, was recruited through random telephone numbers. This method of randomization had been validated locally and subjects who did not attend were closely matched in terms of demographics, health, socioeconomic status and risk factors to those who were enrolled. 17, 18 In 2000-2004, 1944 subjects were followed up in CRISPS-2 and detailed reasons for non-participation have been described previously. 17, 18 The study protocol was approved by the Ethics Committee of the University of Hong Kong and the Institutional Review Board of the Hong Kong West Cluster of Hospitals. Written informed consent was obtained from all participants. After excluding subjects without DNA samples and plasma CRP data, 1925 subjects were included in this analysis. There were 547 subjects with and 1378 subjects without hypertension in CRISPS-2. Among 1378 subjects normotensive in CRISPS-2, 1115 subjects had been followed up in CRISPS-3 in 2005-2008 after a median interval of 5.3 years, 236 of whom had developed hypertension.
Variables of interest
The study procedures in CRISPS have been described previously. [17] [18] [19] Demographic data, including age, sex, smoking, drug treatment and history of cardiovascular diseases were obtained using a standard questionnaire. Hypertension was defined as systolic blood pressure (SBP) X140 mm Hg, diastolic blood pressure (DBP) X90 mm Hg or taking anti-hypertensive medication. Blood pressure was measured using a mercury sphygmomanometer three times by a trained nurse after resting for X10 min. The readings were taken from seated participants in a temperature-controlled quiet room. The Korotkoff V sound was used to determine DBP. The first measurement was to familiarize the subject with the procedure and the sensation of the inflated cuff. The mean of the second and third readings was used for data analysis. Cardiovascular disease was defined as self-reported history of ischaemic heart disease and/or stroke.
Venous blood from a forearm vein was taken and plasma was obtained after centrifugation. Plasma samples were aliquotted and frozen until they were assayed as a batch. CRP was measured in plasma samples of subjects in CRISPS-2, but not in CRISPS-3, using an in-house sandwich enzyme-linked immunosorbent assay established in our laboratory as described previously. 20, 21 SNP selection Tagging SNPs in CRP were selected from the HapMap database on Han Chinese (Phase II data, release 24). 22 Four SNPs (rs2808630, rs1205, rs1800947 and rs3093059) captured all the five SNPs from 5-kb upstream to 2-kb downstream of the gene (position 157 946 704-157 956 003, GenBank accession number NC_000001) with r 2 X0.9 and minor allele frequency X5%. In addition, three SNPs (rs3093068, rs3091244 and rs2794521) from the NCBI dbSNP (Build 36) database were included as their minor allele frequencies are X5% in Asians. Two SNPs, rs1130864 (in complete linkage disequilibrium with rs1417938) and rs1341665, were also included because of previous reports of their association with CRP level in other populations [10] [11] [12] [13] although rs1130864 has a minor allele frequency of 3.3% in the HapMap Han Chinese and rs1341665 is B7.2 kb away from the 5 0 end of the gene. All nucleotide sequences were based on the reverse complemented strand of sequence from the GenBank accession number NC_000001.
Genotyping
Genotyping was performed using iPLEX assay and the MassARRAY system (Sequenom, San Diego, CA, USA) at the Genome Research Centre, University of Hong Kong except rs3091244. The triallelic SNP rs3091244 was genotyped using Taqman probes and ABI 7900HT as described previously. 9 
Statistical analysis
For the relationship between CRP and hypertension, variables were used as covariates in logistic regression analysis if they were significantly different between subjects with and without hypertension.
For variables that were highly correlated such as body mass index and waist circumference, only the variable that explained more of the variance (as assessed by R 2 ), was entered into the model. Variables with a skewed distribution were logtransformed before analysis. Single variant analysis was performed under the assumption of additive allelic effects as the effects of the genetic variants on plasma CRP level tended to be additive ( Figure 1) . In a separate analysis, similar results were obtained under the assumption of dominant allelic effects (data not shown). The SNP spectral decomposition method was used to correct for multiple testing of nine SNPs. 23 The effective number of independent marker loci (M effLi ) was 6 and the experimental-wide significance threshold to keep type 1 error rate at 5% was 0.0085. Haplotypes were tested if their frequencies were X5%. An omnibus test on the locus overall was performed first. The effect of each specific haplotype was compared with all other haplotypes combined when the global P-value was o0.05 in the omnibus test. SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Haploview version 4.1 was used to assess linkage disequilibrium. 24 SNPs and haplotypes were analyzed using the program PLINK (version 1.0.6). 25 
Results
Clinical characteristics of subjects Clinical characteristics of the 1925 subjects at the time of CRISPS-2 are shown in Table 1 . Subjects with prevalent or incident hypertension had significantly higher age, body mass index, blood pressure, triglycerides, fasting glucose, 2-h glucose after oral glucose tolerance test, fasting insulin and homeostasis model assessment of insulin resistance index, and lower high-density lipoprotein cholesterol. In CRISPS-2, subjects with prevalent hypertension were more likely to be men, noncurrent smokers and on medication for hypercholesterolaemia, and had history of cardiovascular disease. The number of subjects with a change in smoking status from CRISPS-2 to CRISPS-3 was small (n ¼ 65) and the change in smoking status was not associated with incident hypertension (P40.05). Subjects with prevalent or incident hypertension had significantly higher CRP level (Po0.001) ( Table 1) .
Association of plasma CRP with blood pressure and hypertension As shown in Table 2 , plasma CRP increased with both SBP and DBP in CRISPS-2 when 320 subjects taking anti-hypertensive medication were excluded from the analysis. Similar results were obtained (both Po0.001) if the blood pressures of these treated subjects were adjusted by adding 10 and 5 mm Hg to their SBP and DBP, respectively. 26 The prevalence of hypertension increased with plasma CRP level in CRISPS-2 after adjusting for age and sex (odds ratio (OR) per quartile ¼ 1.40, Po0.001) ( Table 2 ). This association remained significant in the full adjustment model (OR per quartile ¼ 1.17, P ¼ 0.010).
Among subjects normotensive in CRISPS-2, the incidence of hypertension, as determined in CRISPS-3, also increased with plasma CRP level in CRISPS-2 (OR per quartile ¼ 1.45, Po0.001) ( Table 2 ). This association remained significant in the full adjustment model (OR per quartile ¼ 1.26, P ¼ 0.010). Similar results were obtained after excluding 16 subjects with plasma CRP level 410 mg l À1 , which was considered to reflect clinical inflammation (P ¼ 0.010 for both prevalent and incident hypertension). No significant sex interaction was observed for the association of plasma CRP with prevalent or incident hypertension (P ¼ 0.476 and 0.438, respectively).
Association of SNPs and haplotypes with plasma CRP level In X99.7% of the 1925 subjects, all SNPs were genotyped successfully (Supplementary Table 1 ). Figure 1) . Six of the nine SNPs were significantly associated with CRP level in CRISPS-2 ( Figure 1 ). Among these six SNPs, the minor alleles of the SNPs rs3093068 and rs3093059 (with pairwise r 2 ¼ 0.97) showed the largest effect size for plasma CRP level (increased by 25.7 and 25.3%, respectively) (Supplementary Table 1 ). Similar results were obtained for these 6 SNPs after excluding 16 subjects with plasma CRP level 410 mg l À1 (Po0.001). Haplotypes were then constructed using the six SNPs, rs3093068, rs1205, rs1800947, rs3091244, rs3093059 and rs1341665 that were associated with CRP level. There were five haplotypes with frequencies X5%, namely CAGCTT (43.2%), CGGCTC (22.0%), GGGACC (16.7%), CACCTT (8.9%) and CGGTTC (5.3%). Haplotype analysis showed a similar and significant association with CRP level (global Po0.0001). Haplotype GGGACC, the only haplotype containing the minor G allele at rs3093068, was associated with a 24.0% increase in CRP level (Po0.001) while haplotype CACCTT, the only haplotype containing the minor C allele at rs1800947, was associated with a 20.6% decrease in CRP level (Po0.001). Haplotype CAGCTT was also associated with a 7.0% decrease in CRP level (P ¼ 0.040). Similar trends were obtained in sex-specific analysis (data not shown).
Association of SNPs and haplotypes with hypertension and blood pressure In CRISPS-2, none of the SNPs was significantly associated with prevalent hypertension after adjusting for age and sex (P40.05). Similar results were obtained for quantitative blood pressure traits in CRISPS-2 if 320 subjects on anti-hypertensive medication were excluded or if the blood pressures of these treated subjects were adjusted by 10/5 mm Hg (all P40.05). 26 Among subjects normotensive in CRISPS-2, none of the SNPs was significantly associated with incident hypertension after adjusting for age, sex and follow-up duration (P40.05). Two SNPs showed a nominal association with change in DBP from CRISPS-2 to CRISPS-3, which were not significant after correction for multiple testing ( Table 3) . Analysis of the haplotypes also revealed a similar nonsignificant association with blood pressure, prevalent or incident hypertension, or change in blood pressure (data not shown). The ORs for the association of plasma CRP level with prevalent and incident hypertension remained unchanged after further adjusting for the genotype of each SNP (data not shown).
Discussion
Few studies have investigated the relationship between plasma CRP and risk of developing hypertension in a prospective study design. The study by For blood pressures, subjects on anti-hypertensive medication were excluded (n ¼ 320 and 74 in cross-sectional and prospective analysis, respectively).
b
On anti-hypertensive medication at CRISPS-3. Model 1: adjusted for baseline age and sex in cross-sectional analysis and further adjusted for follow-up duration in prospective analysis. Model 2: adjusted for baseline age, sex, BMI, triglycerides, HDL cholesterol, 2-h post-OGTT glucose, HOMA-IR, current smoking, history of cardiovascular disease and medication for hypercholesterolaemia in cross-sectional analysis, and further adjusted for baseline SBP and follow-up duration in prospective analysis.
Sesso et al. 5 included only women while the study by Dauphinot et al. 6 included exclusively elderly subjects aged X65 years. In our population-based study including Chinese men and women with a wide age range, plasma CRP correlated significantly with both SBP and DBP, and an elevated CRP level was found to be predictive of the development of hypertension. Our results are consistent with the two previous reports, supporting a role of inflammation in the pathogenesis of hypertension. 5, 6 Recent clinical trials showed that lowering CRP level using statin in asymptomatic subjects can prevent cardiovascular events, even in subjects without hyperlipidaemia. 27, 28 However, whether elevated CRP has a direct casual role in cardiovascular diseases or is just a marker of increased risk remains unclear. In fact, traditional cardiovascular risk factors such as smoking, obesity, insulin resistance and all five components of the metabolic syndrome are associated with elevated CRP level. 3, 29 Therefore, elevated CRP could be due to reverse causality. Obesity is known to be associated with both inflammation and hypertension, and may thus confound the relationship between CRP and hypertension. 7, 8 As genotypes are randomly assigned at conception in a way similar to randomized controlled trials, genetic variants are less likely to be influenced by lifestyle factors, disease status and other environmental confounding factors, thus providing a better tool to assess the causal relationship. 30 In this study, several genetic variants were associated with plasma CRP level. Our study confirms previous reports of the association of plasma CRP with genetic variants such as rs3093068, rs1800947, rs1205, rs3091244, rs3093059 and rs1341665. [9] [10] [11] [12] [13] Our study also highlights ethnic differences in the association of genetic variants with plasma CRP level. For example, rs1130864 was significantly associated with plasma CRP in five different British and Australian studies, 31 but this SNP was not associated with plasma CRP level in our study. The SNPs rs1130864 and rs1417938 (in complete linkage disequilibrium with rs1130864) were found to be associated with plasma CRP level in several reports, 10, 11, 13 but not all. 12 Although some SNPs in the CRP gene influenced plasma CRP level and plasma CRP level predicted the development of hypertension in our study, we did not find any significant association between these SNPs and hypertension. Apparently, the elevation in plasma CRP associated with these SNPs per se did not result in an appreciably greater risk of hypertension. Genetic and environmental factors both contribute to the development of hypertension and the elevation in CRP level could be caused by non-genetic factors such as obesity and insulin resistance. Similar to our study, a recent study also revealed a significant association of CRP level, but not genetic variants, with aortic pulse wave velocity, a measure of arterial stiffness. 32 Another study in British elderly women aged 60-79 years found no relationship between blood pressure or hypertension and a CRP gene variant that was associated with CRP level, and the association of CRP level with hypertension was greatly diminished after adjusting for covariates. 7 In a cohort of young American adults aged 18-30 years, the association of CRP with hypertension became insignificant after adjusting for body mass index. 8 In contrast, a recent Turkish study revealed a significant association of genetic variants with plasma CRP and hypertension, 33 although the association might not be significant after correcting for multiple testing. The use of genetic variants as the instrumental variables has suggested that CRP does not have a causal role in the development of other hypertension-related traits, such as insulin resistance, diabetes, atherosclerosis, coronary heart disease, carotid intima-media thickness and the metabolic syndrome in Caucasians. 31, [34] [35] [36] [37] Although elevated CRP is a predictor of adverse cardiovascular outcome, it adds little to current risk prediction models that include established risk factors such as sex, age, total cholesterol, high-density lipoprotein cholesterol, SBP, smoking status and diabetes. 38, 39 In our study, we showed that plasma CRP is an independent predictor for the development of hypertension, which occurs earlier than overt cardiovascular disease in the cardiovascular continuum. 40 Plasma CRP seems better than SNPs in the CRP gene in predicting the future risk of developing hypertension. Higher CRP levels probably reflect genetic as well as environmental factors that predispose to hypertension.
There are several limitations in this study. The cohort of this study is community-based and so the number of people with hypertension is smaller than that in a case control study. Using Genetic Power Calculator, 41 our study had at least 80% power to detect an OR X1.29 for prevalent hypertension in CRISPS-2 at the 5% significance level for the SNPs, rs3093068 and rs3093059, that showed the largest effect size on plasma CRP level (assuming a disease prevalence of 28.4%). In the prospective analysis, only 236 subjects developed hypertension, which may limit the power to detect significant association of SNPs with hypertension. Moreover, the time between follow-up visits when the subjects developed hypertension is unknown. Elevation in plasma CRP level is nonspecific and can be unrelated to inflammation or hypertension. We did not sequence our samples for rare and novel mutations and thus could not exclude the possibility of a causative variant, which has not been genotyped in HapMap or previous studies. However, our study has the advantage of a population-based prospective design and subjects living in a well-defined geographic region. The subjects in this study are younger than those in some previous studies. 6, 7, 33 Moreover, we have analyzed a set of SNPs that capture most of the single-nucleotide variations in the CRP gene and tested the relationship between CRP and hypertension using both cross-sectional and prospective study designs in the same study.
In conclusion, plasma CRP is associated with prevalent and incident hypertension. SNPs in CRP gene are related to plasma CRP level, but not significantly related to hypertension or blood pressure. The future risk of hypertension is therefore more related to plasma CRP than SNPs in the CRP gene. Plasma CRP may be a better marker for newonset hypertension as it reflects genetic as well as environmental factors that predispose to hypertension. Further studies in other populations are needed to confirm these findings.
